Recent/Upcoming Studies
Human Clinical Trials
to study safety, dose-tolerance, and benefits

BioNeutra is proud to announce results from our recently completed human clinical study aiming to study the safety, dose-tolerance and beneficial effects of VitaFiber™-IMO product.

This human clinical study was conducted at KGK Synergize Inc., London, Ontario, Canada. The main objective of the study was to evaluate the safety and dose tolerance of BioNeutra’s manufactured VitaFiber™-IMO, and the data collected is comprised of daily bowel habits, digestive symptoms, and a list of related adverse effects. Moreover, this study included the analysis of VitaFiber™-IMO’s effect upon colon microflora as well as on the clinical chemistry including; prebiotic effect, analysis of short-chain fatty acid (SCFA) and effect on total cholesterol including HDL-C and LDL.

BioNeutra

9608 25 Avenue NW
Edmonton, Alberta T6N 1J4
Canada
Tel: 1.780.466.1481
Fax: 1.780.801.0036

©2017 BioNeutra